🇺🇸 FDA
Patent

US 8138345

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

granted A61KA61K31/444A61K31/4709

Quick answer

US patent 8138345 (Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity) held by Theravance, Inc. expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/444, A61K31/4709, A61K31/56, A61K45/06